Multiplex assays are the type of immunoassays used for the simultaneous detection of multiple analytes from a single sample. Multiplex assays are used increasingly owing to the advantages offered by the assays over singleplex assays. Multiplex assays generate more reproducible and robust results compared to singleplex assays. Multiplex assays are more reliable compared to singleplex assays, can simultaneously analyze multiple analytes, reduce the chances of human error, and offer more accurate results.
The rising prevalence of chronic & infectious diseases is also increasing the demand for multiplex assay diagnostic kits for the simultaneous detection of pathogens in human samples. Multiplex assays also help detect coinfections compared to routine testing methods for improving treatment efficiency. Diagnostic laboratories are increasingly adopting multiplex panel assays to detect gastrointestinal pathogens, sexually transmitted infections, and respiratory infections. For instance, in October 2022, Thermo Fischer Scientific, Inc. (U.S.) launched a CE-IVD Marked TaqPath Enteric Bacterial Select Panel to detect and differentiate between common gastrointestinal pathogens, including Salmonella spp.; Shigella spp./enteroinvasive E. coli (EIEC); Campylobacter jejuni, Campylobacter coli, and Campylobacter upsaliensis. In April 2022, Bruker Corporation (U.S.) launched a New FluoroType STI PCR assay that detects seven sexually transmitted infections pathogens using LiquidArray multiplex PCR technology.
The demand for multiplex assay diagnostic kits increased during the COVID-19 pandemic for detecting and differentiating between COVID-19 virus and other respiratory viruses. Additionally, multiplex assay diagnostic kits were also adopted for detecting COVID-19 virus variants for better treatment outcomes. For instance, in November 2020, QIAGEN N.V. (Netherlands) launched a NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay to detect and differentiate respiratory and COVID-19 virus in Europe and other markets. In September 2020, Seegene, Inc. (South Korea) launched its Allplex SARS-CoV-2/FluA/FluB/RSV Assay, a single-tube RT-PCR assay. The assay is designed to detect and differentiate three different target genes of COVID-19 (S gene, RdRP gene, and N gene): Flu A, Flu B, and RSV A/B.
Pharmaceutical and biotechnology companies are increasingly focusing on personalized medicines, which offer more effective treatments tailored to individual patients based on their genetic makeup. Multiplex assays play a crucial role in this process as they can identify changes in gene expression, genetic variations, or epigenetic modifications associated with specific diseases or conditions. With the rising prevalence of chronic diseases, there is a growing emphasis on accelerating the drug discovery process. Multiplex assays facilitate simultaneous reactions and are widely utilized in both pre-clinical and clinical stages of drug development. They enable the evaluation of drug response biomarkers, immunotherapy efficacy, and toxicity, making them indispensable tools for pharmaceutical and biotechnology companies.
Protein and nucleic acid biomarker information can be utilized to identify pharmacological targets, validate therapeutic hypotheses, and predict the safety of inhibitory compounds targeting specific molecular targets. Multiplex assays can unveil single nucleotide polymorphisms related to diseases, genetic variations, and immune response profiles, providing valuable data for drug discovery. The growing adoption of multiplex assays in developing therapeutic techniques that target specific genes, including gene and oligonucleotide therapy, is expected to accelerate the identification of novel drug targets and significantly contribute to drug development efforts.
Multiplex assays are used in biomarker discovery and validation. Biomarkers can range from expressed RNA to protein or gene sequence. Early discovery and validation of biomarkers are done by multiplex assays, which can lead to a better understanding of disease mechanisms. Identifying and characterizing biomarkers can streamline the drug candidate selection process, reducing the number of failures in clinical trials, enabling the discovery of more effective therapeutics, and providing means to monitor progress in preclinical research and evaluate responses in clinical trial participants.
Rising advantages of multiplex assays, increasing focus on companion diagnostics & personalized medicine, and increasing need for high-throughput and automated systems drive the global multiplex assays market. This is expected to drive the global digital therapeutics market is projected to reach $ 6.24 billion by 2030, at a CAGR of 9.0%, according to Meticulous Research®.
Access Full Report Here @ https://www.meticulousresearch.com/product/multiplex-assays-market-5598